HighTower Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

HighTower Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,000	Closed	-$3.85K	–	3993
2023 Q4	$3.85K	Buy	+7,000	New	+$65.4K	﹤0.01%	3480
2023 Q3	–	Sell	-250	Closed	-$9.5K	–	3747
2023 Q2	$9.5K	Buy	+250	New	+$2.03K	﹤0.01%	3310
2022 Q1	–	Sell	-400	Closed	-$29K	–	3674
2021 Q4	$29K	Sell	400 -205,600	-100%	-$1.86M	﹤0.01%	3076
2021 Q3	$151K	Buy	+206,000	New	+$1.93M	﹤0.01%	2775
2021 Q2	–	Sell	-1,360	Closed	-$107K	–	3380
2021 Q1	$107K	Buy	1,360 +1,260	+1,260%	+$14.4K	﹤0.01%	2748
2020 Q4	$1K	Buy	+100	New	+$958	﹤0.01%	2586
2019 Q3	–	Sell	-2,500	Closed	-$1K	–	2539
2019 Q2	$1K	Buy	+2,500	New	+$30.1K	﹤0.01%	2369

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's TEVA Position: Q1 2026 in Review

HighTower Advisors increased its Teva Pharmaceuticals (TEVA) stake by 24% in Q1 2026, buying an estimated $1.39M and bringing the position to 224,067 shares worth $6.75M. The position accounts for 0.01% of the portfolio, ranked #1054.

HighTower Advisors first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.2M in Q1 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

HighTower Advisors held 224,067 shares of Teva Pharmaceuticals worth $6.75M as of Q1 2026.
HighTower Advisors bought 43,243 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.39M.
Teva Pharmaceuticals made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #1054 holding.
HighTower Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
HighTower Advisors's Teva Pharmaceuticals position peaked at $12.2M in Q1 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.